This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Participate in the study voluntarily, sign the informed consent form.
Subjects were able to provide primary or metastatic cancer samples.
At least one measurable lesion.
Expected survival > 3 months.
Pathologically or radiologically confirmed presence of distant metastatic disease, including lymph nodes above the first lumbar vertebra (L1) (cephalad) or in the inguinal region.
Administering live vaccines within 4 weeks before enrollment or during planned study treatment.
Participants who received immunosuppressive therapy within 4 weeks before enrolment.
For participants who are receiving thrombolytic/anticoagulant therapy, prophylactic anticoagulant therapy is allowed.